Our data suggest that mitochondrial metabolism can be exploited by targeting the DYNLT1-Parkin-VDAC1 axis to further improve the ability of metabolic inhibitors to suppress breast cancers with limited treatment options, such as TNBC, in the future. This evidence concerns the gene DYNLT1 and breast carcinoma.